Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaTropin versus Norditropin NordiLet in prepubertal children with growth hormone deficiency
IRCT20150303021315N12Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of somatropin in Idiopathic Isolated Growth Hormone Deficiency (IGHD) (2 arms), sponsored by CinnaGen. Primary endpoint: Change in height velocity. Started Dec 2018; status: completed.
02
Drugs
somatropin
03
Conditions
Idiopathic Isolated Growth Hormone Deficiency (IGHD)
Beyond the preview
Go deeper on IRCT20150303021315N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N12.